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 1 
Treatment of Intracranial Dural Fistulas with Onyx: A Prospective Cohort, Systematic 1 
review, and Meta-Analysis 2 
Background: Onyx is important embolic material in the treatment of intracranial dural 3 
arteriovenous fistula (DAVF). However, its impact on DAVF occlusion rates, morbidity, 4 
mortality, and complication rates is not fully examined. 5 
Objective: To improve understanding of safety and effectiveness profiles associated with Onyx 6 
treatment of intracranial DAVF 7 
Methods: We analyzed data from our prospective clinical registry and conducted a systematic 8 
review of all previous studies using Onyx published between January 2005 and December 2015 9 
in MEDLINE and EMBASE. 10 
Results: In the prospective study, 41 procedures were performed in 33 consecutive patients 11 
harboring 36 DAVFs. Complete initial exclusion was obtained in 32 of 36 (88.9%) fistulas; 31 12 
fistulas were followed-up showing 4 (12.9%) recurrences. Procedure-related morbidity and 13 
mortality was 3% and 0%, respectively. The literature search identified 19 previous involving 14 
425 patients with 463 DAVFs. Meta-analysis showed an initial complete occlusion rate of 82% 15 
(95% confidence interval [CI]: 74%, 88%; I2, 70.6%), and recurrence rate at mid-term of 2% 16 
(95% CI: 0%, 5%; I2, 21.5%). Pooled post-operative neurologic deficit, procedure-related 17 
morbidity, and mortality rates were 4% (95% CI: 2%, 6%; I2, 0%), 3% (95% CI: 1%, 5%; I2, 0%) 18 
and 0%, respectively.  19 
Conclusion: This meta-analysis suggests that endovascular treatment with Onyx is a safe 20 
treatment modality for DAVFs. Although Onyx showed a low recurrence rate at mid-term, the 21 
long-term risk is poorly addressed in our study and should warrant a longer follow-up. 22 
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Intracranial dural arteriovenous fistulas (DAVFs) account for 10 to 15% of intracranial vascular 23 
malformations and are treated by endovascular approach in the majority of cases (1). Ethylene vinyl 24 
alcohol/dimethyl sulfoxide polymer (Onyx; EV3, Irvine, California) is an important liquid embolic 25 
material in the endovascular treatment (EVT) of intracranial DAVFs. Onyx embolic material has 26 
been extensively used due to its non-adhesive properties, allowing prolonged injection times with 27 
good lesion penetration, and convenient control for the operator (2). Since the introduction of Onyx 28 
in 2005, several single-center studies have demonstrated acceptable rates of DAVF occlusion, 29 
morbidity, and mortality for patients treated with Onyx via trans-arterial approach (3-21).  30 
Improved understanding of safety and effectiveness profiles associated with Onyx treatment 31 
of intracranial DAVF is needed. Thus, we analyzed data from our prospective clinical registry and 32 
conducted a systematic review and meta-analysis of the literature with special interest on 33 
intracranial DAVF occlusion rates, procedure-related complication rates, and recurrence rates at 34 
follow-up for intracranial DAVFs treated with Onyx via trans-arterial approach. 35 
 36 
MATERIALS AND METHODS 37 
Prospective Study 38 
Patients.-This study was approved by the local ethics committee and was found to conform to 39 
scientific principles and research ethics standards. An informed consent was obtained from each 40 
patient. This study was designed, conducted, and analyzed and the article was written independently 41 
of industry or any other financial support. 42 
The population was nested within a longitudinal cohort of consecutive patients who were 43 
referred to our institution for EVT of intracranial DAVFs between January, 2013, and December, 44 
2015. This prospectively maintained database was queried retrospectively to identify all consecutive 45 
patients matching the following inclusion criteria: (a) patients with intracranial DAVFs (b) who 46 
were treated by trans-arterial approach using Onyx.  47 
 3 
EVT and initial angiographic results.-All procedures were performed under general anesthesia and 48 
full heparinization. Complete selective digital subtraction angiography (DSA) was performed 49 
before treatment. An Onyx-compatible microcatheter was coaxially positioned into one of major 50 
arterial feeder as close as possible to the fistula site. First, the dead space of the microcatheter was 51 
flushed with dimethyl-sulfoxide (DMSO), followed by a slow injection of Onyx under subtraction 52 
fluoroscopy. If an Onyx reflux occurred, the injection was paused for 30 to 60 seconds. During 53 
Onyx progression into the shunt, it was continually and slowly injected. The removal of the 54 
microcatheter was done when the Onyx cast stopped advancing or if we had a complete occlusion 55 
of the shunt. A post-operative DSA was performed after the procedure to confirm the complete 56 
occlusion of the DAVF. Initial angiographic results of EVT were classified by a neuroradiologist 57 
not involved in the initial EVT (B.G., with 7 years of experience in neuroimaging) by using the 58 
Cognard classification (22). 59 
Systematic standard follow-up protocol.-After discharge, the systematic follow-up included at least 60 
a clinical examination and DSA at 3 months after EVT for ruptured DAVFs and at 6 months for 61 
unruptured DAVFs.  62 
Clinical follow-up.-Further clinical follow-up data were collected during hospitalization for follow-63 
up DSA or external consultation at 3 months. Post-operative neurologic complication was defined 64 
as any new neurologic symptoms, including cranial nerve palsy. Procedure-related morbidity was 65 
defined as a permanent neurologic deficit including cranial nerve palsy or change in modified 66 
Rankin Scale (mRS) score≥1 at 3 months after the procedure. 67 
Image acquisition and analysis.-Angiographic images were acquired in antero-posterior and lateral 68 
projections before and immediately after treatment. Angiographic images obtained immediately 69 
after EVT were compared with those obtained at angiographic follow-up. At follow-up, we 70 
considered a DAVF recurrence when an early venous opacification was observed at DAVF 71 
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completely occluded regardless of how big it is. In addition, we also considered it as a recurrence 72 
when the type of DAVF was modified. 73 
 74 
Systematic Review 75 
We prepared this study in accordance with the Meta-analysis Of Observational Studies in 76 
Epidemiology and Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines 77 
(23,24), including objectives and plans for collecting and analyzing the data. We performed a 78 
systematic review of the literature by two authors (U.S.G., N.M.) using the keywords “dural 79 
arteriovenous fistula” and “onyx” and “cerebral” or “brain” or “intracranial” in MEDLINE and 80 
EMBASE databases. Inclusion criteria were the following: all type of study design published in 81 
English language, ≥10 patients, from January 2005 to December 2015, where EVT was performed 82 
via a trans-arterial route and where Onyx was used as the embolic material. Exclusion criteria were 83 
the following: case report, studies with duplicate case series, studies with balloon-assisted 84 
technique. 85 
Baseline characteristics of patients and DAVFs.-Clinical data included sex, number of eligible 86 
patients, mean age of patients, and clinical presentation. DAVFs characteristics, procedure-related 87 
complications, morbidity and mortality, anatomical outcomes, and follow-up modality. All the data 88 
were reviewed and collected individually by two authors (S.G.U. and M.N.), and compared. 89 
Disagreements were discussed until a consensus was reached.  90 
Outomes.-Only patients treated with Onyx alone were considered for the calculation of the post-91 
operative complications, morbi-mortality rates after treatment and DAVF recurrence rates. End 92 
points included post-operative neurologic deficit after EVT, including cranial nerve palsy, and 93 
anatomic results obtained at DSA or magnetic resonance angiography. Post-operative neurologic 94 
complication was differentiating as ischemic and hemorrhagic.  95 
 5 
Individual study quality assessment.-The included studies being uncontrolled, individual study 96 
quality was assessed using a checklist published by the National Institutes of Health for before-after 97 
(pre-post) studies with no control group (25). This 12-item checklist enables an assessment of 98 
uncontrolled studies and provides an overall quality rating. Quality assessment was performed 99 
independently by 2 authors (S.G.U. and M.N.). 100 
 101 
Statistical analysis 102 
Systematic review.-The 95% confidence intervals (CIs) of the estimates were built with the Wilson 103 
method. The estimate and the 95% CI of the mean percentage over all the studies were obtained for 104 
each outcome using a logistic mixed model with a random effect on the intercept in order to take 105 
into account the heterogeneity between the studies. In all analyses, inconsistency of findings 106 
throughout studies was assessed by using the p value and the I2 statistic. We searched for 107 
publication bias using Egger's test for small-study effects and presented funnel plots. The meta-108 
analyses were carried out using the metaprop Stata command (26) on Stata/SE 14.1 (Statacorp LP, 109 
College Station TX, USA).  110 
 111 
RESULTS 112 
Prospective Study 113 
Population.-A total of 41 procedures were performed in 33 patients (21 men and 12 women, mean 114 
age, 57.4 years) harboring 36 DAVFs (3 patients had 2 DAVFs). Table 1 provides baseline 115 
characteristics. Initial clinical symptoms were 10 intracranial hemorrhages, 12 tinnitus, and 2 116 
seizures, while the rest of the patients presented with incidentally discovered DAVFs. 117 
Initial angiographic results.-According to Cognard’s classification, 7 cases were type I, 3 cases 118 
were type II a, 8 cases were type II b, 2 cases were type II a+b, 8 cases were type III and 8 cases 119 
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were type IV. Initial complete exclusion of the DAVFs was obtained in 32 of 36 (88.9%) DAVFs. 120 
DAVFs obliterations were achieved in 2 procedures for 5 patients and in 1 procedure for the other 121 
cases. 122 
 Of the 4 partial EVT, the type of DAVF was initially II a (Patient 2), one II b (Patient 15), 123 
one III (Patient 4) and one IV (Patient 13). After EVT, the type II b was reverted to type II a, and 124 
the type III in type I. For the type IV, the occlusion after EVT was partial because of high risk of 125 
facial nerve palsy due to important microcatheter reflux. Thus, considering these 4 patients, 2 126 
procedures were partial due to the risk of nerve palsy or reversion into benign type.  127 
Angiographic results at follow up.-Angiography was obtained in 29 patients harboring 31 DAVFs 128 
(Table 1). A recurrence was observed in 4 DAVFs (12.9%). The 10 initially ruptured DAVF were 129 
totally occluded at follow-up. For initial partial obliteration, 2 patients showed similar DAVF type 130 
(Patients 4 and 15), 1 patient presented complete fistula exclusion at follow-up (Patient 13; a 131 
complementary surgery was performed after EVT failure), and 1 patient presented a type II b 132 
(Patient 2).  133 
Clinical complications.-A total of 3 patients had post-operative neurologic complication following 134 
EVT. Two patients presented a cranial nerve palsy: 1 had a third cranial nerve palsy after treatment 135 
of DAVF type IV located at the anterior temporal lobe with subsequent transitory diplopia and 136 
ophthalmoplegia, which completely resolved 3 months later; and 1 patient had a facial nerve palsy 137 
that quickly improved during the first few days, but partially persisted at 3 months follow-up after 138 
treatment of right lateral sinus fistula type II a+b. After treatment of her second DAVF type II b 139 
located in the superior longitudinal sinus, the patient (Patient 15, Table 1) presented with a left 140 
hemiplegia due to venous infarction, persistent at follow-up (mRS 2).  141 
Procedure-related morbidity and mortality.-In our prospective cohort, the procedure-related 142 
morbidity was 3% (1/33 patients). There was no procedure-related mortality. One patient died due 143 
to a compressive hemorrhage in the posterior fossa due to a type III ruptured DAVF. The hematoma 144 
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was located in the vermis, causing an obstructive hydrocephalus with subsequent ventricular shunt 145 
placement. Emergency embolization was performed without complication during procedure, but 1 146 
month later the patient died from complications of the intracranial hematoma.  147 
 148 
Systematic Review 149 
Of the 424 records that were identified in the initial search, 309 were screened after removal of 150 
duplicates, and 280 were excluded at title or abstract level. Twenty-nine were articles were 151 
reviewed at full-text out of which 19 studies were selected for final analysis (Fig 1). At baseline, 152 
425 patients harboring 463 DAVFs were included. Baseline patient and DAVF characteristics of the 153 
19 included studies are shown in supplemental Table 1. The results of the meta-analysis, including 154 
the present study, are shown in Figure 2 and 3, and Table 2. 155 
Initial angiographic results.-The overall initial complete occlusion rate was 82% (95% CI, 74%, 156 
88%). Analysis of the data suggested significant heterogeneity across studies (p<0.05), the range of 157 
initial complete occlusion rate being 47%-100%. 158 
Angiographic results at follow-up.-The recurrence rate was 2% (95% CI, 0%, 5%). Recurrence rate 159 
was reported at mid-term (mean follow-up, 5 months; range, 3 to 7.5 months (supplemental Table 2, 160 
online). Long-term DAVFs recurrences rates were reported in 2 studies comprising a small sample 161 
size of 45 patients.  162 
Clinical complications.-The pooled post-operative neurologic complications rate was 4% (95% CI: 163 
2%, 6%; I2, 0%). The pooled rate of post-operative cranial nerve palsy was 2% (95% CI: 1%, 4%; 164 
I2, 0%). The rate of cerebral ischemic and hemorrhagic complications rates were 1% (95% CI: 0%, 165 
2%, I2, 0%) and 0% (95% CI: 0%, I2, 0%), respectively (supplemental Figure 1). 166 
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Procedure-related morbidity and mortality.-The pooled procedure-related morbidity rate was 3% 167 
(95% CI, 1%, 5%; I2, 0%) with no statistically significant heterogeneity across studies. There were 168 
no procedure related deaths across the 17 studies.  169 
Quality assessment.-Eighteen studies were retrospective whereas 1 was prospective. All were non-170 
comparative. Studies had large heterogeneity in terms of methods for the assessment of outcomes 171 
(presence or not of an adjudication committee; presence or not of a centralized core laboratory; time 172 
of follow-up). Using the prespecified tool, the quality rating of studies was considered as fair or 173 
poor. The main limitations of studies were as follows: no prespecification of selection criteria for 174 
the study population; no justification of sample size; no independent assessment of outcome 175 
measures across all study participants. Consequently, the risk of bias was significant across studies. 176 
Furthermore, we identified potential publication bias on the rate of total complications. See 177 
supplemental Figure 1 and 2 (online) for funnel plot. 178 
 179 
DISCUSSION  180 
In our systematic review, the rate of recurrence at mid-term follow-up was low after EVT using 181 
Onyx of intracranial DAVFs (2%, 95% CI: 0%, 5%). Although this finding demonstrates the 182 
effectiveness of Onyx in the EVT of cranial DAFVs, we observed a non-negligible rate of DAVFs 183 
angiographic recurrence (12.9%) at 3-6 months in our prospective study. Results at follow-up of 184 
intracranial DAVFs beyond 1 year after EVT are not well known. Longer follow-up period were 185 
reported in 2 studies including only a small number of patients (45 patients). Chandra et al. 186 
observed 0 recurrence of 28 patients at 28 months mean follow-up (9), whereas Ambekar et al 187 
reported 3 (14.3%) recurrences of 21 patients at 14 months mean follow-up (4). This underlines the 188 
importance of long-term follow-up for DAVFs, especially for initially ruptured ones with the risk of 189 
rebleeding. However, we used DSA, which is the “gold standard” modality for follow-up of Onyx-190 
treated DAVFs, in our study and the series included in the systematic review. 191 
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To date, there are several embolic materials to treat DAVFs by endovascular approach 192 
including n-butyl-cyanoacrylate (n-BCA), Onyx, polyvinyl alcohol particles, and coils. To date, the 193 
best embolic material for cranial DAVFs is not well known and comparative studies with good 194 
methodological standard are warranted, which is not the objective in the present study. However, 195 
Rabinov et al. compared the effectiveness of cranial DAVFs EVT with Onyx versus n-BCA (20) in 196 
single center study. Although the sample size was limited (56 fistulas), the initial complete 197 
occlusion rate reported for Onyx was 82% versus 33.3% for n-BCA. A superior durability of the 198 
occlusion with Onyx on follow-up was observed. In a recent single center series of 24 fistulas, the 199 
authors compared intracranial DAVFs embolization with Onyx versus n-BCA and coils, and they 200 
reported initial complete occlusion rate of 66% for Onyx versus 22% for n-BCA (27). A possible 201 
explanation is that DAVFs are complex and heterogenic lesions, with considerable anatomo-202 
pathological diversity, influencing the difficulty of the access and EVT phase. Furthermore, 203 
heterogeneity in operator experience may be another explanation.  204 
Procedure-related morbidity and mortality rates were uniformly low across the studies with 205 
pooled rates of 3% (95% CI, 1%, 5%) and 0%, respectively. This meta-analysis, including our 206 
registry data, demonstrates the safety of EVT of intracranial DAVFs with Onyx, most morbidity 207 
events related to cranial nerve palsy (2%; 95% CI: 1%, 4%). EVT via trans-arterial approach of 208 
lesions close to the skull base, as cranial DAVFs, carries an elevated risk for ischemic nerve injury 209 
(1). As Onyx embolization technique usually utilizes some degree of Onyx reflux, adequate safety 210 
margins should be considered appropriately to minimize inadvertent Onyx migration to clinically 211 
important vascular branches. 212 
 Our study had several limitations. First, the articles included in the systematic review 213 
contained a majority of retrospective studies with a limited number of patients; some included 214 
combined liquid embolic materials. Second, a small number of studies (2 of 20 studies, 45 of 465 215 
patients, 19.6%) with long-term follow-up were eligible. Third, data presentation was not uniform 216 
among the source articles, especially for the procedure-related morbidity definition. Four, it is 217 
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possible that some relevant studies were not taken into account in our systematic review. However, 218 
it is unlikely that this potential publication bias distorted strongly our findings because we found no 219 
evidence of such bias by examining the funnel plots. 220 
 221 
CONCLUSION 222 
EVT of intracranial DAVFs with Onyx via trans-arterial approach is a safe treatment modality for 223 
DAVFs. Although Onyx showed a low recurrence rate at mean follow-up of 5 months, the risk of 224 
long-term recurrence is poorly evaluated in our study, and should warrant a longer follow-up 225 
period, especially in ruptured cases and neuro-aggressive ones. 226 
 227 
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Figure Legends: 301 
Figure 1. Flowchart shows screening and selection of studies for meta-analysis. 302 
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Table 1. Neurologic Hospital Baseline Patient and DAVF characteristics. 
 
Patients Sex Age 
Cognard 
Classification2
3 
Symptoms 
Access 
artery 
Initial complete 
occlusion‡ 
Complicatio
n 
Procedure-related 
morbidity 
Recurrence‡ 
1 M 65 III Non specific MMA Yes No 0 NA 
1* M 65 IV Hemorrhage MMA Yes No 0 NA 
2 F 39 II a Tinnitus MMA Partial (I) No 0 Recurrence (II b) 
3 F 43 IV Non specific MMA Yes CNP (III) 0 NA 
4 M 75 III Hemorrhage MMA Partial (I) No 0 Partial (type I) 
5 F 64 I Tinnitus MMA Yes No 0 NA 
6 M 62 I Tinnitus MMA Yes No 0 NA 
7 M 70 IV Hemorrhage APA Yes No 0 No 
8 M 71 II b Non specific MMA Yes No 0 No 
9 F 38 III Hemorrhage MMA Yes No 0 No 
10 F 59 II b Tinnitus MMA Yes No 0 No 
11 M 50 II b Non specific MMA Yes No 0 No 
12 M 46 II a Tinnitus MMA Yes No 0 No 
13 F 78 IV Hemorrhage MMA Partial No 0 No§ 
14 M 66 I Tinnitus MMA Yes No 0 No 
15 F 56 II b Tinnitus MMA Partial (II a) Ischemia Yes Partial (II a) 
15* F 56 II a+b Tinnitus MMA Yes CNP (VII) 0 Recurrence 
16 F 45 III Hemorrhage PMA Yes No 0 No 
17 M 57 II b Non specific MMA Yes No 0 Recurrence 
17* M 57 II a+b Non specific MMA Yes No 0 No 
18 M 55 I Tinnitus MMA Yes 
Microcatheter 
fracture 
0 No 
19 M 54 IV Seizure MMA Yes No 0 No 
20 F 47 II b Tinnitus MMA Yes No 0 No 
21 F 42 I Tinnitus MMA Yes No 0 No 
22 F 61 III Hemorrhage MMA Yes No 0 No 
23 M 64 I Tinnitus MMA Yes No 0 Recurrence 
24 M 68 IV Non specific OA Yes No 0 No 
25 M 44 II b Non specific SCA Yes No 0 No 
Table1
 Note.-M, male; F, female; NA, non assessed; MMA, middle meningeal artery; OA, ophtalmic artery; OccA, occipital artery; PMA, posterior meningeal 
artery; SCA, superior cerebellar artery; APA, ascending pharengeal artery; CNP, cranial nerve palsy. 
* Patients 1, 15 and 17 had 2 DAVFs.  
‡ Data in parentheses is the type of DAVF according Cognard classification (23).  
§ A complementary surgery was performed after initial EVT failure. 
 
 
26 M 65 IV Non specific OA Yes No 0 No 
27 M 50 III Seizure MMA Yes No 0 No 
28 M 81 II b Hemorrhage MMA Yes No 0 No 
29 M 73 II a Non specific OccA Yes No 0 No 
30 F 48 I Tinnitus MMA Yes No 0 No 
31 M 51 III Hemorrhage MMA Yes No 0 No 
32 M 55 III Non specific MMA Yes No 0 No 
33 M 52 IV Hemorrhage MMA Yes No 0 No 
Table 2. Meta-analysis of safety and efficacy after EVT with Onyx 
 
Outcomes 
Number of 
studies 
Sample 
size 
Pooled rates (95% CI) 
Heterogeneity 
p value I2 
Cranial nerve palsy (n = 13) 16 466* 2% (1%, 4%) 0.96 0.0% 
Post-operative neurologic complications (n = 22) 16 466* 4% (2%, 6%) 0.94 0.0% 
Procedure-related morbidity (n = 17) 16 366** 3% (1%, 5%) 0.53 0.0% 
Procedure-related mortality (n = 0) 17 366** 0% (0%, 0%) 1 0.0% 
Initial complete obliteration (n = 373) 19 463*** 82% (74%, 88%) <0.05 70.6% 
Recurrence (n = 5) 13 263*** 2% (0%, 5%) 0.23 21.5% 
* Number of procedures 
** Number of patients 
*** Number of DAVFs 
Table2
Supplemental Tables: 
 
Supplemental Table 1. Population Baseline Characteristics of the 19 Studies. 
 
 
Author Year 
Sample 
size 
Number of 
DAVFs 
Mean age 
Number of 
procedures 
Number of 
symptomatic 
Number of 
seizure 
Number of 
hemorrhage 
Number of 
tinnitus 
Nogueira RG 2008 12 12 56 17 9 0 4 2 
Cognard C 2008 30 30 62,4 35 28 4 16 2 
Panagiotopoulos V 2009 16 16 61 24 15 NA 5 NA 
Lv X 2009 40 40 43,1 40 40 0 16 10 
Huang Q 2009 14 14 50 15 14 0 12 0 
Chew J 2009 12 12 53,4 13 10 1 3 1 
Saraf R 2010 36 NA NA NA NA NA NA NA 
Macdonald JH 2010 NA 26 NA 28 NA NA NA NA 
Maimon S 2011 17 17 56 20 16 1 5 3 
Hu YC 2011 33 37 NA 39 33 NA NA NA 
De Keukeleire K 2011 20 21 57,2 25 20 1 7 8 
Abud TG 2011 42 44 56 46 40 2 6 16 
Long XA 2012 11 11 51,6 11 11 3 0 10 
Rabinov JD 2013 34 35 56,1 54 34 2 13 14 
Ghobrial GM 2013 12 12 NA 40 12 NA NA NA 
Cha KC 2013 19 19 61 22 15 0 4 2 
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Luo CB 2014 14 14 62 14 14 1 2 4 
Chandra RV 2014 40 41 57 49 30 2 13 14 
Ambekar S 2015 26 26 55,4 28 17 0 8 4 
 
Data are number of patients or DAVFs for which information was available. 
 
Supplemental Table 2. Outcomes of the 19 Studies.  
 
Author 
Technical 
complications 
Cranial 
nerve 
palsy 
Post-operative 
neurologic 
complications 
Procedure-
related 
morbidity 
Morbidity 
definition 
Procedure-
related 
mortality 
Initial 
complete 
occlusion 
Recurrence 
Time of 
follow-
up* 
Nogueira RG 0 0 0 0 NA 
0 
 
10 1 4.4 
Cognard C 1 1 2 2 NA 0 24 0 3 
Panagiotopoulos 
V 
0 0 1 0 
Permanent 
deficit 
0 9 1 3.7 
Lv X 2 2 4 3 mRS 0 25 0 5.4 
Huang Q 1 0 1 0 NA 0 11 1 7.5 
Chew J 1 0 0 0 NA 0 9 0 3.6 
Saraf R NA NA NA NA NA 0 33 0 6 
Macdonald JH NA NA NA 0 NA 0 16 0 NA 
Maimon S 1 1 1 0 
Permanent 
neurologic 
deficit 
0 17 0 7.5 
Hu YC NA NA NA NA 
Permanent 
complication 
0 32 NA NA 
De Keukeleire K 5 1 2 2 
Permanent 
neurologic 
deficit 
0 18 0 6.5 
Abud TG 0 2 2 1 NA 0 40 0 6 
Long XA 2 0 0 0 NA 0 10 1 4.5 
Rabinov JD 4 2 2 3 
Major 
neurological 
adverse events 
0 29 1 3 
Ghobrial GM 0 0 2 3 NA 0 8 NA NA 
Cha KC 0 0 0 0 NA 0 9 NA NA 
Luo CB 2 0 0 0 NA 0 10 0 NA 
Chandra RV 5 2 2 1 
Permanent 
neurologic 
complication 
0 38 2 4.2 
Ambekar S NA NA NA NA NA 0 26 NA NA 
Note.-NA, not assessed. 
Data are number of patients or DAVFs for which information was available. 
* Data are months 
Supplemental Figures : 
Supplemental Figure 1. Crude odds ratios for (A) ischemic cerebral complications, (B) hemorrhagic cerebral complications, (C) funnel plot for 
ischemic complications, and (D) funnel plot for hemorrhagic complications. 
 
Supplemental Figure 2. Funnel plots for (A) initial complete obliteration; (B) recurrence at mid-term; (C) post-operative neurologic 
complications; and (D) procedure-related morbidity. 
 
 
 
